Related Experiment Video
Updated: May 15, 2025
08:09
Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease
Published on: January 7, 2014
6.7K
Evaluation of Additive Neuroprotective Effect of Combination Therapy for Parkinson's Disease Using In Vitro Models
Alexander Shtilbans1,2, Elise Esneault3, Florian Simon3
1Department of Neurology, Hospital for Special Surgery, New York, NY 10021, USA.
Antioxidants (Basel, Switzerland)
|April 29, 2025
Summary
Drug combinations show promise for Parkinson's disease (PD). A study found that combining certain medications, like sodium phenylbutyrate, exenatide, and tauroursodeoxycholic acid, offers additive neuroprotection in PD models.
Area of Science:
- Neuroscience
- Pharmacology
- Stem Cell Biology
Background:
- Parkinson's disease (PD) neurodegeneration involves complex mechanisms, often requiring multifaceted therapeutic approaches.
- Current treatments primarily manage symptoms; disease-modifying therapies are urgently needed.
- Drug repurposing offers a strategy to identify novel therapeutic combinations for PD.
Purpose of the Study:
- To evaluate the efficacy of drug combinations for slowing Parkinson's disease progression.
- To identify synergistic or additive effects of repurposed drugs in preclinical PD models.
- To screen nine selected drugs for neuroprotective and anti-neuroinflammatory properties.
Main Methods:
- Utilized induced pluripotent stem cell-derived dopaminergic neurons (wild-type and PD-patient-derived) and alpha-synuclein triplication models.
- Assessed 44 drug combinations, including sodium phenylbutyrate, terazosin, exenatide, ambroxol, deferiprone, coenzyme-Q10, creatine, dasatinib, and tauroursodeoxycholic acid.
- Measured neuroprotection via neurite length, branching, neuronal survival, neurofilament levels, and neuroinflammation via cytokine release.
Main Results:
- Identified four drug combinations exhibiting additive neuroprotective effects in specific endpoints.
- The combination of sodium phenylbutyrate, exenatide, and tauroursodeoxycholic acid demonstrated significant improvement across four key endpoints.
- This specific combination showed superior efficacy compared to individual drugs in preclinical models.
Conclusions:
- Drug combinations can achieve additive neuroprotective effects in Parkinson's disease models, surpassing individual compound efficacy.
- This research paves the way for developing novel combination therapies aimed at slowing or preventing PD progression.
- Further investigation into these combinations could lead to the first disease-modifying treatment for Parkinson's disease.
Related Concept Videos
01:24Parkinson's Disease: Treatment
161
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
161
01:15Parkinson's Disease: Overview
342
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
342